Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography

Neurological Sciences

Volumn 36, Issue 2, 2015, Pages 269-274

  Shin, Hae Won ^a   Kim, Jae Seung ^b   Oh, Minyoung ^b   You, Sooyeoun ^c   Kim, Young Jin ^b   Kim, Juyeon ^b   Kim, Mi Jung ^b   Chung, Sun Ju ^b  

^a Chung Ang University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Keimyung University   (South Korea)

Author keywords

Clinical characteristics; Differential diagnosis; Dopamine receptor blocking agents; Dopamine transporter; Parkinsonism; Positron emission tomography

Indexed keywords

ALPRAZOLAM; ANTIPARKINSON AGENT; ARIPIPRAZOLE; CHLORPROMAZINE; CLONAZEPAM; DOMPERIDONE; FLUNARIZINE; HALOPERIDOL; ITOPRIDE; LEVODOPA; LITHIUM; METOCLOPRAMIDE; N 3 FLUOROPROPYL 2 BETA CARBOXYMETHOXY 3 BETA (4 IODOPHENYL)NORTROPANE F 18; OLANZAPINE; PAROXETINE; PERPHENAZINE; RADIOPHARMACEUTICAL AGENT; RISPERIDONE; SULPIRIDE; TRIAZOLAM; UNCLASSIFIED DRUG; VALPROIC ACID; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; FLUORINE; TROPANE DERIVATIVE;

ADULT; AGED; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DELUSIONAL DISORDER; DIZZINESS; DOPAMINERGIC NERVE CELL; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG INDUCED PARKINSONISM; DYSKINESIA; DYSPEPSIA; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PARKINSONISM; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PUTAMEN; REST; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREMOR; BRAIN; BRAIN MAPPING; CHEMICALLY INDUCED; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; PARKINSON DISEASE; PATHOPHYSIOLOGY; RADIOGRAPHY; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN; BRAIN MAPPING; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TROPANES;

EID: 84921729551     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-014-1945-8     Document Type: Article

References (28)

1. Barbosa MT, Caramelli P, Maia DP et al (2006) Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord 21:800–808
2. Benito-Leon J, Bermejo-Pareja F, Rodriguez J et al (2003) Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 18:267–274
3. Shin HW, Kim MJ, Kim JS et al (2009) Levosulpiride-induced movement disorders. Mov Disord 24:2249–2253
4. Marti-Masso JF, Poza JJ (1998) Cinnarizine-induced parkinsonism: ten years later. Mov Disord 13:453–456
5. Sethi KD, Patel B, Meador KJ (1989) Metoclopramide-induced parkinsonism. South Med J 82:1581–1582
6. Stephen PJ, Williamson J (1984) Drug-induced parkinsonism in the elderly. Lancet 2:1082–1083
7. Cummings JL, Henchcliffe C, Schaier S et al (2011) The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 134:3146–3166
8. Marshall V, Grosset D (2003) Role of dopamine transporter imaging in routine clinical practice. Mov Disord 18:1415–1423
9. Masilamoni G, Votaw J, Howell L et al (2010) (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Exp Neurol 226:265–273
10. Davis MR, Votaw JR, Bremner JD et al (2003) Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med 44:855–861
11. Kim JS, Oh YS, Kim YI et al (2013) Combined use of (123)I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): a 2-year follow-up study. Arch Gerontol Geriatr 56:124–128
12. Lozano R, Concha MP, Montealegre A et al (2007) Effectiveness and safety of levosulpiride in the treatment of dysmotility-like functional dyspepsia. Ther Clin Risk Manag 3:149–155
13. Tinazzi M, Ottaviani S, Isaias IU et al (2008) [123I]FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord 23:1825–1829
14. Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503–510
15. Tolosa E, Coelho M, Gallardo M (2003) DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 18(Suppl 7):S28–S33
16. Tarsy D (1984) Movement disorders with neuroleptic drug treatment. Psychiatr Clin North Am 7:453–471
17. Booij J, Habraken JB, Bergmans P et al (1998) Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med 39:1879–1884
18. Varrone A, Pellecchia MT, Amboni M et al (2004) Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. Neurology 63:2097–2103
19. Esper CD, Factor SA (2008) Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 23(3):401–404
20. Hardie RJ, Lees AJ (1988) Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 51:850–854
21. Goetz CG (1983) Drug-induced Parkinsonism and idiopathic Parkinson's disease. Arch Neurol 40:325–326
22. Garcia-Ruiz PJ, Garcia de Yebenes J, Jimenez-Jimenez FJ et al (1992) Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol 15(1):19–26
23. Benvenuti F, Baroni A, Bandinelli S et al (1988) Flunarizine-induced parkinsonism in the elderly. J Clin Pharmacol 28(7):600–608
24. Booij J, Kemp P (2008) Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 35(2):424–438
25. Nikolaus S, Antke C, Kley K et al (2010) Pretreatment with haloperidol reduces (123)I-FP-CIT binding to the dopamine transporter in the rat striatum: an in vivo imaging study with a dedicated small-animal SPECT camera. J Nucl Med 50(7):1147–1152
26. Mateos JJ, Lomena F, Parellada E et al (2005) Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology (Berl) 181(2):401–406
27. Chen RC, Chang SF, Su CL et al (2001) Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 57(9):1679–1686
28. Li SC, Schoenberg BS, Wang CC et al (1985) A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 42(7):655–657